BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CLSG / GCEL - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CLSG / GCEL
X-ORIGINAL-URL:https://clsg.ca
X-WR-CALDESC:Events for CLSG / GCEL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260625T190000
DTEND;TZID=America/New_York:20260625T203000
DTSTAMP:20260531T192031Z
CREATED:20260531T190709Z
LAST-MODIFIED:20260531T192031Z
UID:10000026-1782414000-1782419400@clsg.ca
SUMMARY:EHA 2026 Update
DESCRIPTION:We invite you to join us to discuss selected acute leukemia abstracts from EHA 2026. \nThe following faculty will be sharing their thoughts on specific abstracts: \nAML \n\nBrian Leber\, McMaster University\, Hamilton\, Ontario\nKristjan Paulson\, University of Manitoba\, Winnipeg\, Manitoba\nLynn Savoie\, University of Calgary\, Calgary\, Alberta\n\n\nJulie Bergeron\, Université de Montréal\, Montréal\, Québec\nJill Fulcher\, University of Ottawa\, Ottawa\, Ontario\n\nWhen: Thursday\, June 25\, 2026\, from 7:00 to 8:30 PM EST. \nWhere: Zoom – link will be provided upon registration.
URL:https://clsg.ca/event/eha-2026-update/
CATEGORIES:Webinars
LOCATION:https://clsg.ca/event/eha-2026-update/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260420T190000
DTEND;TZID=America/New_York:20260420T203000
DTSTAMP:20260418T173716Z
CREATED:20260320T021510Z
LAST-MODIFIED:20260418T173716Z
UID:10000025-1776711600-1776717000@clsg.ca
SUMMARY:The Evolving Treatment Landscape of Adult Ph+ve ALL: The CLSG-ALL-2 Study
DESCRIPTION:We invite you to join a discussion about the upcoming CLSG-ALL-2 Trial. \nTopics to be discussed include: \n\nA brief historical perspective on Ph+ve ALL treatment\nOptimal TKI choice and ‘chemo-free’ TKI/blinatumomab combinations\nCanadian drug approvals and the PhALLCON study\nThe upcoming CLSG-ALL-2 study: SC Blinatumomab + Ponatinib in treatment-naïve Ph+ve ALL\n\nWhen: Monday\, April 20\, 2026 at 7:00 PM EST. \nWhere: Zoom – link will be provided upon registration. \nFaculty: \nBrian Leber\, McMaster University\, Ontario\nJoseph Brandwein\, U of A\, Alberta\nAndre Schuh\, U of T\, Ontario \n 
URL:https://clsg.ca/event/the-evolving-treatment-landscape-of-adult-phve-all-the-clsg-all-2-study/
CATEGORIES:Webinars
LOCATION:https://clsg.ca/event/the-evolving-treatment-landscape-of-adult-phve-all-the-clsg-all-2-study/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260223T190000
DTEND;TZID=America/New_York:20260223T203000
DTSTAMP:20260203T220823Z
CREATED:20260203T220028Z
LAST-MODIFIED:20260203T220823Z
UID:10000024-1771873200-1771878600@clsg.ca
SUMMARY:Management of FLT3-Mutated AML: What’s New in 2026?
DESCRIPTION:We invite you to join a discussion about the management of FLT3-mutated AML and what’s new in 2026. \nThe discussion will cover the impact of newly available Quizartinib on Canadian practice\, and recent advances in FLT3-ITD MRD testing. \nWhen: Monday\, February 23\, 2026 at 7:00 Pm EST. \nWhere: Zoom – link will be provided upon registration. \nFaculty:\nJulie Bergeron\, Hôpital Maisonneuve-Rosemont\, Montréal QC \nHubert Tsui\, Sunnybrook Health Sciences Centre\, Toronto ON
URL:https://clsg.ca/event/management-of-flt3-mutated-aml-whats-new-in-2026/
CATEGORIES:Webinars
LOCATION:https://clsg.ca/event/management-of-flt3-mutated-aml-whats-new-in-2026/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250930T190000
DTEND;TZID=America/New_York:20250930T203000
DTSTAMP:20250929T223730Z
CREATED:20250726T210321Z
LAST-MODIFIED:20250929T223730Z
UID:10000023-1759258800-1759264200@clsg.ca
SUMMARY:Controversies in the Management of AML in the Elderly 2025: An FAQ-Based Discussion
DESCRIPTION:We are planning a series of webinars in the coming months to discuss Acute Leukemia management dilemmas. The first one will be a discussion of ongoing questions in the administration of AML in the Elderly. We hope that you will join the conversation. \nTopics to be discussed include:\n\nDetermination of fitness for standard induction chemotherapy\, VEN/AZA\, and Aza monotherapy\nGenetic Risk stratification/outcome prediction for patients receiving less intensive treatment for AML\nUp-front treatment selection based on specific biology: NPM1\, IDH1\, FLT3-ITD\, TP53\nMaintenance therapy\nVenetoclax dosing/schedules\nWhat is the best bridge to transplant for borderline patients?\n\n\nWe sincerely apologize but we had to change the date of the upcoming CLSG Webinar from Thursday\, September 25 to Tuesday\, September 30th.  \nNew date: Thursday\, September 30\, 2025 @7:00 PM EST \nWhere:Zoom – link will be provided upon registration.  \n\nFaculty:\nJoe Brandwein\, Edmonton \nMahmoud Elsawy\, Halifax \nBrian Leber\, Hamilton\, \nMitch Sabloff\, Ottawa \nAndre Schuh\, Toronto
URL:https://clsg.ca/event/controversies-in-the-management-of-aml-in-the-elderly-2025/
CATEGORIES:Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200917T180000
DTEND;TZID=America/New_York:20200917T190000
DTSTAMP:20231211T212337Z
CREATED:20200818T152239Z
LAST-MODIFIED:20231211T212337Z
UID:10000010-1600365600-1600369200@clsg.ca
SUMMARY:CLSG/GCEL Launch Webinar 3
DESCRIPTION:The founding members of the Canadian Leukemia Study Group are pleased to invite you to a one hour on-line CLSG/GCEL launch event. \nThe founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada\, by identifying diagnostic and management best practices\, promoting Canada-wide standards-of-care\, fostering clinical and basic leukemia research\, and improving new drug access. \nThe objectives of this launch event are to: \n\nIntroduce the Canadian acute leukemia community  to CLSG\, including its founding principles and goals\, mandate\, and scope of interest\nPresent and discuss potential projects\, and solicit feedback and input from webinar participants\nIdentify potential working group topics and interested participants
URL:https://clsg.ca/event/clsg-launch-webinar-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200915T170000
DTEND;TZID=America/New_York:20200915T180000
DTSTAMP:20231211T212325Z
CREATED:20200818T152138Z
LAST-MODIFIED:20231211T212325Z
UID:10000009-1600189200-1600192800@clsg.ca
SUMMARY:CLSG/GCEL Launch Webinar 2
DESCRIPTION:The founding members of the Canadian Leukemia Study Group are pleased to invite you to a one hour on-line CLSG/GCEL launch event. \nThe founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada\, by identifying diagnostic and management best practices\, promoting Canada-wide standards-of-care\, fostering clinical and basic leukemia research\, and improving new drug access. \nThe objectives of this launch event are to: \n\nIntroduce the Canadian acute leukemia community  to CLSG\, including its founding principles and goals\, mandate\, and scope of interest\nPresent and discuss potential projects\, and solicit feedback and input from webinar participants\nIdentify potential working group topics and interested participants
URL:https://clsg.ca/event/clsg-launch-webinar-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200909T160000
DTEND;TZID=America/New_York:20200909T170000
DTSTAMP:20231211T212316Z
CREATED:20200818T151932Z
LAST-MODIFIED:20231211T212316Z
UID:10000008-1599667200-1599670800@clsg.ca
SUMMARY:CLSG/GCEL Launch Webinar 1
DESCRIPTION:The founding members of the Canadian Leukemia Study Group are pleased to invite you to a one hour on-line CLSG/GCEL launch event. \nThe founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada\, by identifying diagnostic and management best practices\, promoting Canada-wide standards-of-care\, fostering clinical and basic leukemia research\, and improving new drug access. \nThe objectives of this launch event are to: \n\nIntroduce the Canadian acute leukemia community  to CLSG\, including its founding principles and goals\, mandate\, and scope of interest\nPresent and discuss potential projects\, and solicit feedback and input from webinar participants\nIdentify potential working group topics and interested participants
URL:https://clsg.ca/event/clsg-launch-webinar-1/
END:VEVENT
END:VCALENDAR